Clinical Trials

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05401110 2026-03-04

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

60 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06741085 2026-02-18

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

56 enrolled

Non Small Cell Lung Cancer Metastatic

NCT07379476 2026-02-12

Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer

64 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07375316 2026-02-10

A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positvie ctDNA After lead-in Osimertinib Monotherapy

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05624996 2026-01-14

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Phase 3 Recruiting

474 enrolled

Lung Neoplasms

NCT04780568 2025-12-09

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

24 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07058519 2025-11-26

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

250 enrolled

Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)

NCT04410796 2025-11-06

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

571 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06304441 2025-09-29

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Phase NA Recruiting

100 enrolled

CNS

Meningeal Carcinomatosis

NCT04762199 2025-05-09

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

69 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06014827 2025-05-04

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

32 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05281406 2025-02-21

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06071013 2025-01-23

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Phase 1/2 Recruiting

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04322890 2024-10-22

PIKACHU

6,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT06362980 2024-07-10

EGFR

20 enrolled

NSCLC

NCT06306456 2024-07-08

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

Phase 1/2 Recruiting

94 enrolled

Non-Small Cell Lung Cancer With EGFR Mutation

NCT06486142 2024-07-03

ERIS

Phase 3 Recruiting

200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04085315 2024-06-10

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

38 enrolled

Lung Cancer Metastatic

NCT06109558 2024-05-30

PROFILE

Phase 1/2 Recruiting

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05528458 2024-04-23

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

59 enrolled

Adenocarcinoma of Lung

NCT04772235 2024-04-03

TOTEM

32 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05011487 2024-01-16

NOCE01

30 enrolled